Attached files
| file | filename |
|---|---|
| 10-Q - 10-Q - RECURSION PHARMACEUTICALS, INC. | rxrx-20210331.htm |
| EX-31.2 - EX-31.2 - RECURSION PHARMACEUTICALS, INC. | exhibit312-q0121.htm |
| EX-31.1 - EX-31.1 - RECURSION PHARMACEUTICALS, INC. | exhibit311-q0121.htm |
| EX-10.2 - EX-10.2 - RECURSION PHARMACEUTICALS, INC. | exhibit102-q0121.htm |
| EX-10.1 - EX-10.1 - RECURSION PHARMACEUTICALS, INC. | exhibit101-q0121.htm |
Exhibit 32.1
Certifications of Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
In connection with the Quarterly Report of Recursion Pharmaceuticals, Inc. (the “Company”) on Form 10-Q for the period ended March 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
/s/ Christopher Gibson
Christopher Gibson, Chief Executive Officer (principal executive officer)
/s/ Michael Secora
Michael Secora, Chief Financial Officer (principal financial officer)
Date: May 12, 2021